A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Nature Medicine2000Vol. 6(8), pp. 879–885
Citations Over TimeTop 1% of 2000 papers
Fadlo R. Khuri, John Nemunaitis, Ian Ganly, James C. Arseneau, Ian F. Tannock, L. Romel, Martin Gore, J. Ironside, R.H. MacDougall, Carla Heise, Britta Randlev, Ann M. Gillenwater, Patricia A. Bruso, Stanley B. Kaye, Waun Ki Hong, David H. Kirn
Related Papers
- → The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin(2001)86 cited
- → Antitumor effect of radioactive cisplatin (191Pt) on nude mice(2001)37 cited
- Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.(1994)
- → Treatment with Paclitaxel Alone Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-resistant Ovarian Carcinoma(2000)10 cited
- The Relationship between Expression of 1-Cys Peroxiredoxin and Resistance to Cisplatin in Epithelial Ovarian Cancer Cell Lines.(2006)